Mecarbinate is a novel and potent anti-hepatitis C virus (HCV) agent.
Daclatasvir (formerly BMS-790052; EBP-883; trade name Daklinza), a direct-acting antiviral agent, is a selective inhibitor of HCV NS5A (nonstructural protein) with an EC50 of 9-50 pM.
Daclatasvir dihydrochloride (BMS790052; EBP883; BMS-790052; EBP-883; Daklinza), the dihydrochloride salt of Daclatasvir, is a novel, highly potent and selective HCV NS5A protease inhibitor that has been approved in 2014 in EU for use in combination with sofosbuvir for the treatment of hepatitis C (HCV) by causing a decrease in serum HCV RNA levels.
Lomibuvir (also called VX-22; S-1480; VCH222; VX22; S1480; VX222; VCH-222; VX-222) is a novel, potent and selective non-nucleoside inhibitor/NNI of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase with IC50s in the range of 0.94-1.2 μM.
Danoprevir (formerly ITMN-191, R-7227; RO-5190591; RG 7227; RG-7227; trade name Ganovo) is an orally bioavailable and 15-membered macrocyclic peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50s in the range of 0.2-3.5 nM.
Elbasvir (formerly known as MK-8742; MK8742; trade name Zepatier) is a potent NS5A (nonstructural protein 5A) inhibitor with anti-HCV (hepatitis C virus) activities against different HCV genotypes.
Ombitasvir (trade name; Viekira Pak; formerly known as ABT-267) is a novel and potent N-phenylpyrrolidine-based inhibitor of hepatitis C virus (HCV) NS5A with excellent potency, metabolic stability, and pharmacokinetics/PK.
Paritaprevir (formerly ABT-450; ABT450; Veruprevir; Viekirax; Viekira Pak; Technivie) is an acylsulfonamide analog and a component of the anti-HCV drug combination therapies: Viekira Pak (Paritaprevir+ombitasvir, ritonavir and dasabuvir) and Technivie (Paritaprevir+ombitasvir and ritonavir).
Telaprevir (also known as LY570310; VX-950; MP424; trade names: Incivek; Incivo), a marketed medication for HCV treatment, is a selective, and reversible peptidomimetic inhibitor of HCV NS3-4A serine protease with an IC50 of 0.35 μM.
Pibrentasvir (formerly ABT-530; ABT530, A-1325912; A1325912; trade name: Mavyret; Maviret), an HCV NS5A protease inhibitor, is an approved antiviral (anti-HCV) drug developed by Abbvie for treating HCV infections.